Comparative Pharmacology
Head-to-head clinical analysis: DURLAZA versus PYRIDAMAL 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURLAZA versus PYRIDAMAL 100.
DURLAZA vs PYRIDAMAL 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Durlaza (aspirin) irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting thromboxane A2 synthesis and reducing platelet aggregation.
Dipyridamole inhibits platelet phosphodiesterase, reducing platelet aggregation; also inhibits adenosine deaminase and increases extracellular adenosine, leading to vasodilation.
325 mg orally once daily
100 mg orally three times daily.
None Documented
None Documented
2-4 hours (prolonged in renal impairment; up to 10-20 hours in severe impairment). Clinical dosing adjustments required when CrCl <30 mL/min.
Terminal half-life 10-12 hours; clinical context: steady state achieved in 3-5 days; renal impairment prolongs half-life
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal. Negligible hepatic metabolism.
Renal: 50-70% unchanged; biliary/fecal: 20-30% as metabolites; total renal elimination ~85%
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent